Comparison of malignancy and spatial distribution between latent and clinical prostate cancer: an 8-year biopsy study

Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consisten...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medical research Vol. 27; no. 1; pp. 1 - 8
Main Authors Zhen, Liang, Zhien, Zhou, Hanzi, Huang, Xingcheng, Wu, Yu, Xiao, Wenze, Wang, Yuzhi, Zuo, Yuliang, Chen, Yi, Zhou, Weigang, Yan
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 10.09.2022
BioMed Central
BMC
Subjects
Age
Autopsies
Autopsy
Biopsy
Cancer
Cancer surgery
Diagnosis
Latent cancer
Malignancy
Oncology, Experimental
Patients
Prostate cancer
Software
Spatial distribution
Tumors
Urological surgery
Japan
Online AccessGet full text

Cover

Abstract Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria. Methods Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. Results In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP [greater than or equal to] 2, 12.5% had tumor volume [greater than or equal to] 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP [greater than or equal to] 2, and 82.5% had tumor volume of [greater than or equal to] 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. Conclusion The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor. Keywords: Autopsy, Latent cancer, Prostate cancer, Spatial distribution, Malignancy
AbstractList Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria. Methods Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. Results In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP [greater than or equal to] 2, 12.5% had tumor volume [greater than or equal to] 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP [greater than or equal to] 2, and 82.5% had tumor volume of [greater than or equal to] 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. Conclusion The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor. Keywords: Autopsy, Latent cancer, Prostate cancer, Spatial distribution, Malignancy
Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria. Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP [greater than or equal to] 2, 12.5% had tumor volume [greater than or equal to] 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP [greater than or equal to] 2, and 82.5% had tumor volume of [greater than or equal to] 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.
Abstract Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria. Methods Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. Results In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP ≥ 2, 12.5% had tumor volume ≥ 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP ≥ 2, and 82.5% had tumor volume of ≥ 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. Conclusion The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.
Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria. Methods Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant. Results In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP ≥ 2, 12.5% had tumor volume ≥ 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP ≥ 2, and 82.5% had tumor volume of ≥ 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3. Conclusion The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.
Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria.BACKGROUNDCurrent prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to investigate whether the tumor pathological origin of latent prostate cancer (lPCa) and clinical prostate cancer (cPCa) are consistent, and to verify the current clinically significant prostate cancer criteria.Prostate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant.METHODSProstate specimens were obtained from postmortem autopsy between 2014 and 2021 and patients who went through radical prostatectomy from 2013 to 2021. The pathological characteristics and spatial distribution of the lPCa group and cPCa group were compared and analyzed through SPSS software with P < 0.05 representing statistical significant.In lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP ≥ 2, 12.5% had tumor volume ≥ 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP ≥ 2, and 82.5% had tumor volume of ≥ 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3.RESULTSIn lPCa group, a total of 45 tumor lesions from 24 lPCa cases were included, 54.2% of lPCa patients were ISUP ≥ 2, 12.5% had tumor volume ≥ 0.5 ml, and 16.7% had extraprostatic extension (EPE). In cPCa group, there were a total of 429 tumor lesions in 126 cases, 92.1% of cPCa patients were ISUP ≥ 2, and 82.5% had tumor volume of ≥ 0.5 ml. 36.3% had EPE. LPCa and cPCa have the same spatial distribution characteristics, and no significant difference was detected between the anterior and posterior zone. Peripheral zone tumors were significantly more common than transitional zone tumors. Tumors in apical 1/3 and middle 1/3 were significantly more common than basal 1/3.The malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.CONCLUSIONThe malignancy of cPCa is significantly higher than that of lPCa, and the spatial distribution of cPCa and lPCa is consistent. ISUP grade 2 is not sufficient to determine clinical significance of tumor.
ArticleNumber 175
Audience Academic
Author Yuliang, Chen
Yi, Zhou
Xingcheng, Wu
Wenze, Wang
Weigang, Yan
Zhen, Liang
Zhien, Zhou
Hanzi, Huang
Yu, Xiao
Yuzhi, Zuo
Author_xml – sequence: 1
  givenname: Liang
  surname: Zhen
  fullname: Zhen, Liang
– sequence: 2
  givenname: Zhou
  surname: Zhien
  fullname: Zhien, Zhou
– sequence: 3
  givenname: Huang
  surname: Hanzi
  fullname: Hanzi, Huang
– sequence: 4
  givenname: Wu
  surname: Xingcheng
  fullname: Xingcheng, Wu
– sequence: 5
  givenname: Xiao
  surname: Yu
  fullname: Yu, Xiao
– sequence: 6
  givenname: Wang
  surname: Wenze
  fullname: Wenze, Wang
– sequence: 7
  givenname: Zuo
  surname: Yuzhi
  fullname: Yuzhi, Zuo
– sequence: 8
  givenname: Chen
  surname: Yuliang
  fullname: Yuliang, Chen
– sequence: 9
  givenname: Zhou
  surname: Yi
  fullname: Yi, Zhou
– sequence: 10
  givenname: Yan
  surname: Weigang
  fullname: Weigang, Yan
BookMark eNp9kktr3DAUhU1JadI0f6ArQ6F041QvW3IXhTD0EQh0k0V34lqPGQ2y5Ep2y_z7amZSmgmlaCFx9Z1zke55WZ2FGExVvcboGmPRvc8MIYQbREiDkNifnlUXBDHecEG_nz06n1dXOW8LjTrS8b5_UZ3TDglBmbiollUcJ0gux1BHW4_g3TpAULsagq7zBLMDX2uX5-SGZXYFG8z8y5hQe5hNmA-c8i44VcApxTyXeq2Kh0kfym0tmp2BVA8uTnlX53nRu1fVcws-m6uH_bK6__zpfvW1ufv25XZ1c9eoluO5MUNvKcMDYhYwHQxQjjG0bWt7zK3SghAOuus63VJtdG8RYMSItmTosab0sro92uoIWzklN0LayQhOHgoxrSWk2SlvpKXFwirTK0IYYwpaA6jFggMHwzpcvD4evaZlGI1W5ekJ_Inp6U1wG7mOP2XPOsYQKQbvHgxS_LGYPMvRZWW8h2DikiXhmIiWcsEL-uYJuo1LCuWn9lRLqeCM_KXWUB7ggo2lr9qbyhuOO9EK0qNCXf-DKkub0amSKetK_UTw9pFgY8DPmxz9Yfb5FBRHUJWh52SsVK7MvmClg_MSI7lPqjwmVZakykNS5V5Knkj__ON_RL8BNQPraQ
CitedBy_id crossref_primary_10_1016_j_semcancer_2023_03_007
Cites_doi 10.1002/pros.10177
10.1111/j.1464-410X.2004.05146.x
10.1016/j.juro.2017.05.075
10.1002/pros.24091
10.1016/j.juro.2009.05.018
10.1097/JU.0000000000000804
10.1016/j.juro.2015.11.068
10.1093/jnci/djm153
10.1038/nrurol.2013.112
10.1038/sj.pcan.4500847
10.1002/ijc.2910200506
10.1016/j.juro.2012.05.006
10.5152/dir.2014.13322
10.1111/pin.12513
10.1097/PAS.0b013e31812f7b27
10.1016/S0090-4295(02)01525-X
10.1001/jama.1994.03510290050036
10.1097/00000478-198812000-00001
10.1111/bju.12458
10.1159/000516681
10.1016/j.urology.2012.08.012
10.1016/j.euf.2019.06.014
10.1093/jnci/djt151
10.3322/caac.21708
10.2144/fsoa-2020-0154
10.1038/pcan.2013.54
10.1002/pros.22903
10.1097/00000478-199612000-00009
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s40001-022-00801-0
DatabaseName CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2047-783X
EndPage 8
ExternalDocumentID oai_doaj_org_article_f353dfce9c22444ca5ea05187a7ae461
PMC9464402
A716858290
10_1186_s40001_022_00801_0
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: ;
  grantid: No: 2020-I2M-C&T-B-021
GroupedDBID ---
0R~
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBD
EBLON
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
UKHRP
PMFND
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c571t-eb9f341b04fa13bea3711a555f917fcd8227ad666d53ded9f0a1042df2b91d33
IEDL.DBID M48
ISSN 2047-783X
0949-2321
IngestDate Wed Aug 27 01:28:52 EDT 2025
Thu Aug 21 14:11:33 EDT 2025
Fri Jul 11 06:04:36 EDT 2025
Fri Jul 25 07:34:44 EDT 2025
Tue Jun 17 21:48:55 EDT 2025
Tue Jun 10 20:35:01 EDT 2025
Thu May 22 21:07:16 EDT 2025
Tue Jul 01 02:25:14 EDT 2025
Thu Apr 24 23:09:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c571t-eb9f341b04fa13bea3711a555f917fcd8227ad666d53ded9f0a1042df2b91d33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2715338742?pq-origsite=%requestingapplication%
PMID 36088348
PQID 2715338742
PQPubID 2040181
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_f353dfce9c22444ca5ea05187a7ae461
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9464402
proquest_miscellaneous_2712853787
proquest_journals_2715338742
gale_infotracmisc_A716858290
gale_infotracacademiconefile_A716858290
gale_healthsolutions_A716858290
crossref_citationtrail_10_1186_s40001_022_00801_0
crossref_primary_10_1186_s40001_022_00801_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-10
PublicationDateYYYYMMDD 2022-09-10
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-10
  day: 10
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle European journal of medical research
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Mygatt (801_CR19) 2014; 17
R Takashima (801_CR30) 2002; 59
V Iremashvili (801_CR25) 2012; 80
T Hossack (801_CR20) 2012; 188
C J (801_CR7) 2021; 26
HA Al-Ahmadie (801_CR18) 2008; 32
M Sánchez-Chapado (801_CR24) 2003; 54
JI Epstein (801_CR4) 1994; 271
SA Rice (801_CR6) 2013; 185
T Kimura (801_CR13) 2016; 195
N Breslow (801_CR16) 1977; 20
JE McNeal (801_CR21) 1988; 12
PE Teloken (801_CR28) 2017; 198
K Stamatiou (801_CR22) 2006; 9
GP Haas (801_CR23) 2007; 99
B Garvey (801_CR11) 2014; 20
G Tarantino (801_CR2) 2021; 7
Y Zhou (801_CR29) 2021; 81
NB Delongchamps (801_CR12) 2009; 182
TH Van der Kwast (801_CR5) 2013; 10
M Perera (801_CR8) 2014; 113
AR Zlotta (801_CR15) 2013; 105
S Sato (801_CR17) 2017; 67
AR Schned (801_CR9) 1996; 20
RL Siegel (801_CR1) 2022; 72
M Massanova (801_CR10) 2021; 105
JJ Lee (801_CR26) 2015; 75
H Inaba (801_CR14) 2020; 204
A Erbersdobler (801_CR27) 2004; 94
M Maggi (801_CR3) 2020; 6
References_xml – volume: 54
  start-page: 238
  issue: 3
  year: 2003
  ident: 801_CR24
  publication-title: Prostate
  doi: 10.1002/pros.10177
– volume: 94
  start-page: 122
  issue: 9
  year: 2004
  ident: 801_CR27
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2004.05146.x
– volume: 198
  start-page: 131
  issue: 6
  year: 2017
  ident: 801_CR28
  publication-title: J Urol
  doi: 10.1016/j.juro.2017.05.075
– volume: 81
  start-page: 135
  issue: 2
  year: 2021
  ident: 801_CR29
  publication-title: Prostate
  doi: 10.1002/pros.24091
– volume: 182
  start-page: 927
  issue: 3
  year: 2009
  ident: 801_CR12
  publication-title: J Urol
  doi: 10.1016/j.juro.2009.05.018
– volume: 204
  start-page: 267
  issue: 2
  year: 2020
  ident: 801_CR14
  publication-title: J Urol
  doi: 10.1097/JU.0000000000000804
– volume: 195
  start-page: 1415
  issue: 5
  year: 2016
  ident: 801_CR13
  publication-title: J Urol
  doi: 10.1016/j.juro.2015.11.068
– volume: 99
  start-page: 1484
  issue: 19
  year: 2007
  ident: 801_CR23
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djm153
– volume: 10
  start-page: 473
  issue: 8
  year: 2013
  ident: 801_CR5
  publication-title: Nat Rev Urol
  doi: 10.1038/nrurol.2013.112
– volume: 9
  start-page: 45
  issue: 1
  year: 2006
  ident: 801_CR22
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/sj.pcan.4500847
– volume: 20
  start-page: 680
  issue: 5
  year: 1977
  ident: 801_CR16
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910200506
– volume: 188
  start-page: 781
  issue: 3
  year: 2012
  ident: 801_CR20
  publication-title: J Urol
  doi: 10.1016/j.juro.2012.05.006
– volume: 20
  start-page: 229
  issue: 3
  year: 2014
  ident: 801_CR11
  publication-title: Diagn interv radiol
  doi: 10.5152/dir.2014.13322
– volume: 67
  start-page: 156
  issue: 3
  year: 2017
  ident: 801_CR17
  publication-title: Pathol Int
  doi: 10.1111/pin.12513
– volume: 32
  start-page: 229
  issue: 2
  year: 2008
  ident: 801_CR18
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e31812f7b27
– volume: 59
  start-page: 692
  issue: 5
  year: 2002
  ident: 801_CR30
  publication-title: Urology
  doi: 10.1016/S0090-4295(02)01525-X
– volume: 271
  start-page: 368
  issue: 5
  year: 1994
  ident: 801_CR4
  publication-title: JAMA
  doi: 10.1001/jama.1994.03510290050036
– volume: 12
  start-page: 897
  year: 1988
  ident: 801_CR21
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-198812000-00001
– volume: 113
  start-page: 29
  issue: Suppl 2
  year: 2014
  ident: 801_CR8
  publication-title: BJU Int
  doi: 10.1111/bju.12458
– volume: 105
  start-page: 804
  issue: 9–10
  year: 2021
  ident: 801_CR10
  publication-title: Urol Int
  doi: 10.1159/000516681
– volume: 80
  start-page: 1063
  issue: 5
  year: 2012
  ident: 801_CR25
  publication-title: Urology
  doi: 10.1016/j.urology.2012.08.012
– volume: 6
  start-page: 463
  issue: 3
  year: 2020
  ident: 801_CR3
  publication-title: Eur Urol Focus
  doi: 10.1016/j.euf.2019.06.014
– volume: 185
  start-page: 132
  issue: 1
  year: 2013
  ident: 801_CR6
  publication-title: Rev Urol
– volume: 105
  start-page: 1050
  issue: 14
  year: 2013
  ident: 801_CR15
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djt151
– volume: 26
  start-page: 100
  year: 2021
  ident: 801_CR7
  publication-title: Cancer Treat Res Commun
– volume: 72
  start-page: 1
  year: 2022
  ident: 801_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21708
– volume: 7
  start-page: FSO643
  issue: 3
  year: 2021
  ident: 801_CR2
  publication-title: Future Sci OA.
  doi: 10.2144/fsoa-2020-0154
– volume: 17
  start-page: 75
  issue: 1
  year: 2014
  ident: 801_CR19
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2013.54
– volume: 75
  start-page: 183
  issue: 2
  year: 2015
  ident: 801_CR26
  publication-title: Prostate
  doi: 10.1002/pros.22903
– volume: 20
  start-page: 1501
  issue: 12
  year: 1996
  ident: 801_CR9
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-199612000-00009
SSID ssj0000626799
Score 2.3110425
Snippet Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present...
Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the present study is to...
Abstract Background Current prostate cancer (PCa) screening may detect nonprogressive lesion, leading to overdiagnosis and overtreatment. The purpose of the...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Age
Autopsies
Autopsy
Biopsy
Cancer
Cancer surgery
Diagnosis
Latent cancer
Malignancy
Oncology, Experimental
Patients
Prostate cancer
Software
Spatial distribution
Tumors
Urological surgery
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_Sg3gRrYpja40geJChM5lkknirxVKEeqrQW8inFurs0t097H_ve5nssKOgF2_L5AV23kfe7zEvv0fIO9VrF8GwtQMHqXlUTe2UxR53H1VykJHzFIWrr_3lN_7lRtzsjfrCnrCRHnhU3GnqRBeSj9pDsuHcWxEtOJKSVtrIx8IHct5eMTWewayXWu9uyaj-dMWb3D0EtReiJPg1y0SZsP_PY_n3Vsm93HPxhDwuoJGejX_2KXkQh0Py8Kp8Fn9GNufTNEG6SPQnYOvvSKSxpXYIdIVN07A9IEduGW9FS38WvQOsOayz3O6SJF3iTRB4Tj26xP1HWKWq3kJMUHe7WK62NJPSPifXF5-vzy_rMk-h9kK26zo6nSBpuYYn23Yu2k62rRVCJKjZkg-AFaQNUM8EUHkMOjUWijUWEnO6DV33ghwMiyG-JJS7EJVVysXWAaJLWigWhNW-9amVja5Iu1Ot8YVrHEde3Jlcc6jejOYwYA6TzWGainyY9ixHpo2_Sn9Ci02SyJKdH4DvmOI75l--U5E3aG8zXjmdYt2cQRGpBH5irsj7LIHRDi_gbbm0AGpA3qyZ5PFMEqLUz5d3PmXKKbEyTCLaVpKzirydlnEndr4NcbHJMgwgFZyrFZEzX5y9-3xluP2RmcI1B7jbsFf_Q1lH5BHL0aMhdR-Tg_X9Jr4GQLZ2Jzn2fgGqwDNP
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA-6gngRP7G6agTBg5Rt-pXEi6yLyyKspxXeLeRzXdhtn6_vHd5_70yaVquwt9JMKOlkJr9JJr8h5L1opfGg2NzABMlrL4rcCI057taLYGBFjlUUzr-3Zz_qb6tmlTbchpRWOfnE6Khdb3GP_KjkiEwERHKf179yrBqFp6uphMZdcg-pyzCli6_4vMdSAFrncqTbq2UO4IFN92ZEezTURcwngmgMcRM8LdamSOH_v6P-N3nyr9Xo9BF5mGAkPR71_pjc8d0Tcv88HZQ_JbuTub4g7QO9AbR9idQae6o7RwdMo4buDllzU8ErmjK26DWgz24b5aZrk3SNd0PgPbU4STafoJWKfA9WQs1Vvx72NNLUPiMXp18vTs7yVGEhtw1n29wbGWAZM0UdNKuM1xVnTDdNEyCKC9YBeuDaQYTjmsp5J0OhIXwrXSiNZK6qnpODru_8C0Jr47zQQhjPDGC8AMooXaOlZTYwXsiMsOnXKpvYx7EIxrWKUYho1agOBepQUR2qyMjHuc965N64VfoLamyWRN7s-KLfXKpkhipUMJBgvbQAXera6sZrcEuCa6593bKMvEV9q_ES6mz96hjCStHgoXNGPkQJtH8YgNXpGgP8BmTSWkgeLiTBbu2yeZpTKvmNQf2Z5Rl5NzdjT8yF63y_izIlgCzwtBnhi7m4GPuypbv6GbnDZQ0AuChf3v7xV-RBGe1CwjJ9SA62m51_DeBra95EC_sNvHcsQA
  priority: 102
  providerName: ProQuest
Title Comparison of malignancy and spatial distribution between latent and clinical prostate cancer: an 8-year biopsy study
URI https://www.proquest.com/docview/2715338742
https://www.proquest.com/docview/2712853787
https://pubmed.ncbi.nlm.nih.gov/PMC9464402
https://doaj.org/article/f353dfce9c22444ca5ea05187a7ae461
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bi9QwFA57AfFFvGJ1HSMIPki1adMmEURml12WgVlEd2HeQq7rwtiOcwHn33uStoPVRZ9maE4GknP7zvRcEHrNK6EdMDbVICApdTxLNVchx9047jV45DhFYXpRnV_Ryayc7aF-3FF3gatbQ7swT-pqOX_388f2Eyj8x6jwvHq_ollMDIKwKgAg-LaPDsEzsaCo0w7ut5Y5r5ho2-9RkQKYIH0dza0_M_BVsaX_34b7z2TK37zT2X10r4OVeNzKwQO05-qH6M60e3H-CG1OdvMGcePxd0Df16HVxhar2uJVSKuG7TZ00e0GYOEugwvPAY3W60jXl1HiRagVgefYBKFZfoBVzNMtaA3WN81itcWxbe1jdHl2enlynnYTF1JTMrJOnRYe3JrOqFek0E4VjBBVlqWHqM4bC2iCKQsRjy0L66zwmYJwLrc-14LYoniCDuqmdk8Rpto6rjjXjmjAfF6UPLelEoYYT1gmEkT6q5Wm60YehmLMZYxKeCVbdkhgh4zskFmC3u72LNpeHP-kPg4c21GGPtrxQbO8lp1aSl_AQbxxwgCUodSo0ikwU5wpphytSIJeBn7Ltih1Zw3kGMJMXoaX0Al6EymChMIBjOrKGuAaQmetAeXRgBL02AyXe5mSvRrInAU8zhnNE_Rqtxx2hty42jWbSJMD6ALLmyA2kMXB2Ycr9c232EtcUADEWf7sv-d8ju7mUTUEeO4jdLBebtwLwGNrPUL7bMZG6HA8nnydwOfx6cXnL6P478YoKuAvEQE1dA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxQxFA5lC-qLeMXRaiMoPsjQyezMTiKItLVla7uLyAp9C7nWQp1Z94Lsj_I_ek7moqPQt74tkxOW5FzyneRcCHnFR0I7YGysQUDizPEk1lxhjLtx3Gs4kUMXhcl0NP6afTrPz7fIrzYXBsMqW5sYDLWtDN6R76UFIhMOntyH-Y8Yu0bh62rbQqMWi1O3-Qku2_L9yUfg7-s0PT6aHY7jpqtAbPKCrWKnhQfTrZPMKzbUTg0LxlSe5x48F28snJiFsoDqbT60zgqfKHBZUutTLZjF-0-w-NvZEDyZAdk-OJp-_tJd6iTgHhSiru-XiRjQCmsTdfhob5klIYAJ3D8EavCrdxiGngH_nwz_Rmv-dfwd3yN3G9xK92tBu0-2XPmA3Jo0L_MPyfqwa2hIK0-_A7y_wFoeG6pKS5cYtw3TLZbpbTps0SZEjF4B3C1Xga7N06RzTEaB79SgVC7ewSjl8Qb2n-rLar7c0FAX9xGZ3cTmPyaDsirdE0IzbR1XnGvHNIBKL3Ke2lwJw4xnRSIiwtqtlaYpd45dN65kcHv4SNbskMAOGdghk4i87ebM62If11IfIMc6SizUHT5UiwvZ6L30Q1iIN04YwEpZZlTuFNhBXqhCuWzEIrKL_JZ11mtnbuQ--LE8x1fuiLwJFGhwYAFGNXkTsA1YuqtHudOjBENh-sOtTMnGUC3lH7WKyMtuGGdi8F3pqnWgSQHVgWmPSNGTxd7a-yPl5bdQrFxkgLiT9On1f75Lbo9nkzN5djI9fUbupEFHBGCEHTJYLdbuOSC_lX7R6Bsl8oY1_Dda-Gp7
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+malignancy+and+spatial+distribution+between+latent+and+clinical+prostate+cancer%3A+an+8-year+biopsy+study&rft.jtitle=European+journal+of+medical+research&rft.au=Hanzi%2C+Huang&rft.au=Yuliang%2C+Chen&rft.au=Zhien%2C+Zhou&rft.au=Yuzhi%2C+Zuo&rft.date=2022-09-10&rft.pub=BioMed+Central+Ltd&rft.issn=0949-2321&rft.volume=27&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-022-00801-0&rft.externalDBID=n%2Fa&rft.externalDocID=A716858290
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon